Physician profile
Bruce Black
NPI 1730199290
$16,920.17
in general payments reported to CMS, 2019-2025
59 companies · $2,355 in 2025
The $2,355 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,817 · 2020: $2,294 · 2021: $2,118 · 2022: $2,318 · 2023: $2,589 · 2024: $2,429 · 2025: $2,355.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,373.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,373.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,742.20 | 2019-2025 | Vraylar, Ubrelvy, Qulipta |
| Astrazeneca Pharmaceuticals Lp | $1,569.00 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Pfizer INC. | $1,328.30 | 2019-2025 | |
| Lilly USA, LLC | $966.00 | 2019-2025 | Mounjaro, Zepbound, Emgality |
| Novo Nordisk INC | $925.11 | 2019-2025 | Ozempic, Rybelsus, Tresiba |
| Merck Sharp & Dohme LLC | $828.69 | 2019-2024 | Verquvo, Belsomra, Steglatro |
| Glaxosmithkline, LLC. | $783.97 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Takeda Pharmaceuticals U.S.A., INC. | $721.21 | 2019-2025 | Trintellix |
| Allergan, INC. | $564.05 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $540.06 | 2019-2024 | Xarelto, Spravato |
| Amarin Pharma, INC. | $495.76 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $409.84 | 2019-2025 | Jardiance, Synjardy, Ofev |
| Esperion Therapeutics, INC. | $388.43 | 2020-2025 | Nexletol |
| Amgen INC. | $374.19 | 2019-2025 | Repatha, Otezla, Repatha |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $330.94 | 2019-2025 | Xifaxan, Trulance |
Show all 59 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bruce Black listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.